ClinicalTrials.gg
CompletedNCT02014636Updated Mar 3, 2020

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

A Phase 1 interventional study of Pazopanib and MK-3475 in Carcinoma, Renal Cell, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 45 studies testing pazopanib in Carcinoma, Renal Cell — 1 open to participants now, 4 under way, 1 of them phase 3. pazopanib · Carcinoma, Renal Cell.

Enrollment
25th of 45
42 · median 44
Started
2013
with 1 other
Phase 1
10 of 45
none open now
Registered
36th of 45
by date
Lead sponsor
8 of 45
Novartis Pharmaceuticals

Among the 45 studies testing pazopanib in Carcinoma, Renal Cell, this one is the 25th largest by enrollment, is one of 2 that started in 2013, is one of 10 in phase 1, and was the 36th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 45 studies testing pazopanib in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pazopanib

pazopanib: first FDA approval 2009 (VOTRIENT), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing pazopanib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This is an open-label, 2 part study of pazopanib and/or MK 3475 in treatment naïve subjects with advanced RCC. Part 1 consists of a Phase I dose escalation of pazopanib + MK 3475 followed by an expansion cohort to determine the maximum tolerated regimen and the recommended Phase II dose. Part 2 is a randomized 3-arm Phase II study to evaluate the clinical efficacy and safety of pazopanib + MK 3475 as compared to single-agent pazopanib and single-agent MK 3475. The objectives of this Phase I/II study are to test the safety and tolerability of pazopanib in combination with MK 3475, and study the clinical efficacy of pazopanib in combination with MK 3475 in subjects with advanced RCC as compared with single-agent pazopanib and single-agent MK 3475.

Following the Urgent Safety Measure (USM) released on February 09, 2017, the phase II (Part 2) portion of this study will not commence.

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • Pazopanib (GW786034)
  • MK 3475
  • Renal cell carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written before performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up
  • Diagnosis of locally advanced or RCC that is predominantly clear cell histology
  • Must have
  • Subject has received no prior systemic therapy
  • A woman is eligible to participate in the study if she is of Non-, has a negative serum pregnancy test within 7 days of the first dose of study treatment, not lactating, and agrees to use adequate during the study until at least 120 days after the last dose of product
  • performance status 0 or 1
  • Adequate organ function as defined in the protocol
  • >= lower limit of normal as assessed by echocardiogram or multigated acquisition scan
  • In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion criteria

Exclusion Criteria:

  • Subject has an active disease or a documented history of autoimmune disease or syndrome that requires systemic or agents
  • Subject is currently participating or has participated in a study of an agent or using an investigational device within 30 days of the first dose of study treatment
  • Subject is expected to require any other form of systemic or localized antineoplastic therapy while on study
  • Subject is on any systemic steroid therapy, within one week before the planned date for first dose of study treatment. Subject is on any other form of immunosuppressive medication
  • Subject has a history of a (other than the disease under treatment in the study) within 5 years before first study treatment administration
  • Central nervous system
  • Unable to swallow and retain orally administered medication
  • Subject has interstitial lung disease or a history of pneumonitis
  • Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other Gastrointestinal conditions with increased risk of perforation; history of abdominal fistula, GI perforation, or intra-abdominal abscess within 4 weeks before beginning study treatment
  • Known history of infection or a known history of or is positive for or
  • Presence of active infection requiring systemic therapy
  • interval duration prolongation
  • History of any one or more of the following cardiac conditions within the past 6 months: Cardiac angioplasty or stenting; Myocardial infarction; Unstable angina; History of Class III or IV congestive heart failure according to classification
  • History of cerebrovascular accident within the past 6 months
  • Poorly controlled hypertension
  • History of untreated deep venous thrombosis
  • Presence of any non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease
  • Evidence of bleeding diathesis or coagulopathy
  • Recent hemoptysis
  • Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage
  • Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining or compliance to the study procedures
  • Previous severe reaction to another Monoclonal antibody. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the in pazopanib tablets
  • Has taken any prohibited medications that are listed in the protocol within 14 days of the first dose of study treatment. Subject has received or will receive a within 30 days before the first administration of study treatment
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part 1

    Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.

    Drug: Pazopanib · Drug: MK-3475

  • Experimental
    Part 2

    Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm: Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy

    Drug: Pazopanib · Drug: MK-3475

Interventions

  • Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg

  • MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs )

    Time frame: From the start of study treatment (first dose) and, until the post-treatment follow-up visit (at least 30 days after the last dose of investigational product) for AEs, and until 90 days after last dose for SAEs

  2. Part 1: To determine the dose limiting toxicity (DLT) and maximum tolerated regimen (MTR)

    MTR is defined as the highest dose of pazopanib in combination with the highest dose of MK 3475 at which no more than 1 of 6 subjects experiences a DLT after a minimum of 8 weeks of treatment. DLT is defined as a drug-related AE starting in the first 8 weeks of treatment

    Time frame: 8 weeks

  3. Part 1: Number of subjects with permanent discontinuation of treatment, dose reductions, interruptions, or delays

    Time frame: 24 months

  4. Part 1: Change from baseline in laboratory parameters

    Laboratory assessments include haematology, clinical chemistry, urine, coagulation and thyroid function test

    Time frame: Average of 4 years

  5. Part 1: Change from baseline in vital signs

    Vital sign measurements will include heart rate, temperature and blood pressure

    Time frame: 30 days after the last dose of study treatment

  6. Part 1: Change from baseline in cardiac parameters

    Cardiac assessments will include Electrocardiogram (ECG) and Echocardiograms (ECHOs)

    Time frame: 24 months

  7. Part 1: Incidence and titer of anti MK 3475 antibodies

    Subjects will be monitored for anti-MK 3475 antibodies throughout the study

    Time frame: 24 months

  8. Part 2: Progression-free survival (PFS)

    PFS is defined as the interval between the date of randomization and the earlier date of disease progression (using RECIST v1.1) or death due to any cause.

    Time frame: Average of 4 years

Secondary outcomes

  1. Part 1: Dose escalation cohorts: pazopanib plasma concentrations and serum MK 3475 concentrations.

    For analysis of plasma pazopanib and serum MK 3475 concentrations, blood samples will be collected from all subjects

    Time frame: For Pazopanib: before and after the 1st and 2nd dose of MK-3475. For MK-3475: Until 6 months after the last dose of MK-3475

  2. Part 1: Pharmacokinetic (PK) parameters in Expansion cohort

    Area under the plasma concentration-time curve from time 0 to 24 hrs (AUC\[0-24\], maximum observed concentration (Cmax), tmax, and concentration at 24 hours (C24) of pazopanib; Pre-dose (trough) concentration at the end of the dosing interval (Ctau), and apparent clearance following oral dosing CL/F of pazopanib will be determined if data permit.

    Time frame: For Pazopanib: before and after the 1st and 2nd dose of MK-3475. For MK-3475: Until 6 months after the last dose of MK-3475

  3. Part 1 and Part 2: Overall response rate (ORR)

    Overall response rate is defined as the percentage of subjects, who achieved either a confirmed complete response (CR) or partial response (PR) by RECIST v1.1 and modified RECIST

    Time frame: Average of 4 years

  4. Part 1 and Part 2: Clinical benefit rate

    Clinical benefit rate is defined as a confirmed response of CR or PR or at least 6-months stable disease by RECIST v1.1 and modified RECIST.

    Time frame: Average of 4 years

  5. Part 1 and Part 2: Time to response

    Time to response is defined for all subjects with a confirmed CR or PR as per RECIST v1.1as the time from randomization until the first documented evidence of CR or PR (whichever status is recorded first)

    Time frame: Average of 4 years

  6. Part 1 and Part 2: Duration of response

    Duration of response is defined for all subjects with confirmed CR or PR as the time from the first documented evidence of CR or PR until time of first documented disease progression or death due to any causes, whichever is first by RECIST v1.1 and modified RECIST

    Time frame: Average of 4 years

  7. Part 2: PFS by modified RECIST

    Time frame: Average of 4 years

  8. Part 1 and Part 2: Progression-free survival rate at 18 months (PFSR18)

    PFSR18 will be calculated based on Kaplan-Meier estimates of Progression-free survival (PFS) at 18 months by RECIST v1.1 and modified RECIST

    Time frame: 18 months

  9. Part 2: Overall survival (OS) at 18 months

    Overall survival at 18 months will be summarized based on the Kaplan-Meier method.

    Time frame: 18 months

  10. Part 2: Overall survival (OS)

    Overall survival will be summarized using Kaplan-Meier survival curves

    Time frame: Average of 4 years

  11. Part 2: Incidence and severity of AEs and SAEs

    Time frame: From the start of study treatment (first dose) and, until the post-treatment follow-up visit (at least 30 days after the last dose of investigational product) for AEs, and until 90 days after last dose for SAEs

  12. Part 2: Number of subjects with permanent discontinuation of treatment, dose reductions, interruptions, or delays

    Time frame: Average of 4 years

  13. Part 2: Change from baseline in laboratory parameters

    Laboratory assessments include haematology, clinical chemistry, urine, coagulation and thyroid function test

    Time frame: Average of 4 years

  14. Part 2: Change from baseline in vital signs

    Vital sign measurements will include heart rate, temperature and blood pressure

    Time frame: Average of 4 years

  15. Part 2: Change from baseline in cardiac parameters

    Cardiac assessments will include ECG and ECHOs

    Time frame: Average of 4 years

  16. Part 2: Incidence and titer of anti MK 3475 antibodies in patients treated with pazopanib + MK 3475 and single-agent MK 3475

    Subjects will be monitored for anti-MK 3475 antibodies throughout the study

    Time frame: Until 6 months after the last dose of MK-3475

  17. Part 2: PK parameters in randomized phase

    For analysis of plasma pazopanib and serum MK 3475 concentrations, blood samples will be collected from all subjects. AUC\[0-24\], Cmax, tmax, and C24 of pazopanib alone and in combination with MK 3475; Cmax, Ctau, and apparent clearance following oral dosing CL/F of pazopanib will be determined if data permit.

    Time frame: For Pazopanib: Until Dose 49 of MK-3475.

07

Study locations

6 sites
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02215, United States
  • Novartis Investigative Site
    New York, New York 10065, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37203, United States
  • Novartis Investigative Site
    Manchester, Lancashire M20 4BX, United Kingdom
  • Novartis Investigative Site
    London, W1G 6AD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Feb 2019, 62 months.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 62 months is above that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2013
First posted
Dec 18, 2013
StartActual
Dec 27, 2013
Primary completionActual
Feb 27, 2019
CompletionActual
Feb 27, 2019
Last update
Mar 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02014636
Responsible party
Sponsor
First posted
Dec 18, 2013
Start date
Dec 27, 2013
Primary completion
Feb 27, 2019
Completion
Feb 27, 2019
Last update
Mar 3, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pazopanib · Pembrolizumab

Start the discussion